Trade Mark Journal No.2026/028 10 July 2026

UK00004409420 30 June 2026 (5)

TREZULDO

International priority date claimed: 18 May 2026 (United States of America) (99830479)

Class 5: Pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy; Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP